[New drugs for severe asthma].

Area of Science:

• Immunology
• Pulmonology
• Pharmacology

Background:

• Asthma is a common, complex respiratory disease with varied symptoms and immune responses.
• Current standard treatments include inhaled corticosteroids and long-acting beta-agonists, effective for most patients.
• Severe asthma presents challenges with poor symptom control, frequent exacerbations, and persistent airflow limitation despite optimal therapy.

Purpose of the Study:

• To review current therapeutic strategies for asthma, focusing on severe cases.
• To discuss the emerging role and efficacy of monoclonal antibodies in severe asthma treatment.
• To highlight the need for cost-effectiveness and population-specific analyses of novel biologic therapies.

Main Methods:

• Review of current clinical guidelines and therapeutic standards for asthma.
• Analysis of recent studies and clinical trial data on monoclonal antibodies targeting specific inflammatory pathways (IgE, IL-5, IL-4, IL-13).
• Discussion of diagnostic challenges and treatment considerations for severe asthma phenotypes.

Main Results:

• Monoclonal antibodies show promise in treating severe asthma by targeting Th2-driven eosinophilic inflammation.
• Current advanced therapies primarily focus on eosinophilic inflammation, with less focus on non-eosinophilic or Th1 inflammation.
• Identifying specific patient populations and assessing the cost-effectiveness of these expensive biologics are critical next steps.

Conclusions:

• While new biologic therapies offer hope for severe asthma, their application requires precise patient selection.
• Further evaluation of cost-effectiveness and financial impact is essential for integrating these treatments into community healthcare.
• Addressing diverse inflammatory profiles beyond Th2 is crucial for comprehensive severe asthma management.